Top

Published in:

Open Access 01-12-2021 | Migraine | Short report

Association between response to triptans and response to erenumab: real-life data

Authors: Ilaria Frattale, Valeria Caponnetto, Alfonsina Casalena, Maurizio Assetta, Maurizio Maddestra, Fabio Marzoli, Giannapia Affaitati, Maria Adele Giamberardino, Stefano Viola, Amleto Gabriele, Francesca Pistoia, Davide Cerone, Carmine Marini, Simona Sacco, Raffaele Ornello

Published in: The Journal of Headache and Pain | Issue 1/2021

Abstract

Background

Triptans and erenumab are both migraine-specific agents acting on the calcitonin gene-related peptide pathway. Therefore, response to triptans might be associated with response to erenumab.

Main body

In our study, consecutive patients referring to the Headache Centers of the Abruzzo region from January 2019 to March 2020 and treated with erenumab were interviewed about past use and efficacy of triptans. Triptan users were classified as ‘triptan responders’ if they were headache-free 2 h after treating ≥3 migraine attacks with ≥1 triptan. We considered patients as ‘erenumab responders’, if they had a ≥ 50% mean reduction in monthly migraine days between the 4th and the 6th month from treatment start compared with baseline. Of 91 triptan users, 73 (80.2%) were triptan responders and 58 (63.7%) were erenumab responders. The odds ratio of being erenumab responder was 3.64 (95% CI, 1.25–10.64) for triptan users as compared to non-users. (P = 0.014). Besides, starting erenumab improved triptan response in both erenumab responders and non-responders.

Conclusions

Our data of an association between response to triptans and response to erenumab can be useful for patient advice and to improve the understanding of migraine pathophysiology and treatment.

Global Burden of Disease 2016 Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 11:954–976. https://doi.org/10.1016/S1474-4422(18)30322-3CrossRef

De Matteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S (2020) Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother:1–15. https://doi.org/10.1080/14737175.2020.1772758

Tiseo C, Ornello R, Pistoia F, Sacco S (2019) How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice. J Headache Pain 20(1):49. https://doi.org/10.1186/s10194-019-1000-5CrossRefPubMedPubMedCentral

Edvinsson L (2017) The Trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 57(Suppl 2):47–55. https://doi.org/10.1111/head.13081CrossRefPubMed

Ahn AH, Basbaum AI (2005) Where do triptans act in the treatment of migraine? Pain. 115(1–2):1–4. https://doi.org/10.1016/j.pain.2005.03.008CrossRefPubMedPubMedCentral

De Vries P, Villalón CM, Saxena PR (1999) Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 375(1–3):61–74. https://doi.org/10.1016/s0014-2999(99)00197-1CrossRefPubMed

Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33(1):48–56. https://doi.org/10.1002/ana.410330109CrossRefPubMed

Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA (2019) Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol 18(8):795–804. https://doi.org/10.1016/S1474-4422(19)30185-1CrossRefPubMedPubMedCentral

Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, Central Italy. J Headache Pain. 21:32. https://doi.org/10.1186/s10194-020-01102-9

10.

Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1–211. https://doi.org/10.1177/0333102417738202CrossRef

11.

Sarchielli P, Pini LA, Zanchin G, Alberti A, Maggioni F, Rossi C et al (2006) Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia. 26(3):257–265. https://doi.org/10.1111/j.1468-2982.2005.01016.xCrossRefPubMed

12.

Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F et al (2017) A controlled trial of Erenumab for episodic migraine. N Engl J Med 377(22):2123–2132. https://doi.org/10.1056/NEJMoa1705848CrossRefPubMed

13.

Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39(2):175–191. https://doi.org/10.3758/bf03193146CrossRefPubMed

14.

Barbanti P, Aurilia C, Egeo G, Fofi L (2019) Erenumab: from scientific evidence to clinical practice-the first Italian real-life data. Neurol Sci 40(Suppl 1):177–179. https://doi.org/10.1007/s10072-019-03839-xCrossRefPubMed

15.

Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61. https://doi.org/10.1186/s10194-020-01127-0CrossRefPubMedPubMedCentral

16.

Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 21:1–69. https://doi.org/10.1186/s10194-020-01143-0CrossRef

17.

Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A et al (2020) Erenumab in chronic migraine patients who previously failed five first-line Oral prophylactics and OnabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol 11:417. https://doi.org/10.3389/fneur.2020.00417CrossRefPubMedPubMedCentral

18.

Kanaan S, Hettie G, Loder E, Burch R (2020) Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 40(13):1511–1522. https://doi.org/10.1177/0333102420946725

19.

Matteo E, Favoni V, Pascazio A, Pensato U, Benini M, Asioli GM et al (2020) Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna headache center. Neurol Sci 41(Suppl 2):483–484. https://doi.org/10.1007/s10072-020-04667-0

20.

Cheng S, Jenkins B, Limberg N, Hutton E (2020) Erenumab in chronic migraine: an Australian experience. Headache 60(10):2555–2562. https://doi.org/10.1111/head.13968

21.

Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434. https://doi.org/10.1016/S1474-4422(17)30083-2CrossRefPubMed

22.

Lovati C, Giani L, Mariotti D, Alessandro C, Tabaee Damavandi P, Mariani C, Pantoni L (2018) May migraine attack response to triptans be a predictor of the efficacy of Onabotulinum toxin-a prophylaxis? Neurol Sci 39(Suppl 1):153–154. https://doi.org/10.1007/s10072-018-3388-0CrossRefPubMed

23.

Eren OE, Gaul C, Peikert A, Gendolla A, Ruscheweyh R, Straube A (2020) Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients. Sci Rep 10(1):11382. https://doi.org/10.1038/s41598-020-68149-1CrossRefPubMedPubMedCentral

24.

Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF (2020) Mechanism of action of OnabotulinumtoxinA in chronic migraine: a narrative review. Headache 60(7):1259–1272. https://doi.org/10.1111/head.13849

25.

Burstein R, Zhang X, Levy D, Aoki KR, Brin MF (2014) Selective inhibition of meningeal nociceptors by botulinum neurotoxin type a: therapeutic implications for migraine and other pains. Cephalalgia. 34(11):853–869. https://doi.org/10.1177/0333102414527648CrossRefPubMedPubMedCentral

26.

Melo-Carrillo A, Strassman AM, Nir RR, Schain AJ, Noseda R, Stratton J et al (2017) Fremanezumab-a humanized monoclonal anti-CGRP antibody-inhibits thinly Myelinated (Aδ) but not unmyelinated (C) meningeal Nociceptors. J Neurosci 37(44):10587–10596. https://doi.org/10.1523/JNEUROSCI.2211-17.2017CrossRefPubMedPubMedCentral

27.

Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6. https://doi.org/10.1186/s10194-018-0955-yCrossRefPubMedPubMedCentral

Title: Association between response to triptans and response to erenumab: real-life data
Authors: Ilaria Frattale
Valeria Caponnetto
Alfonsina Casalena
Maurizio Assetta
Maurizio Maddestra
Fabio Marzoli
Giannapia Affaitati
Maria Adele Giamberardino
Stefano Viola
Amleto Gabriele
Francesca Pistoia
Davide Cerone
Carmine Marini
Simona Sacco
Raffaele Ornello
Publication date: 01-12-2021
Publisher: Springer Milan
Keywords: Migraine
Headache
Triptan Drugs
Rizatriptan
Erenumab
Published in: The Journal of Headache and Pain / Issue 1/2021
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-020-01213-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Association between response to triptans and response to erenumab: real-life data

Abstract

Background

Main body

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Main body

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

The baton changed hands

Activation of CamKIIα expressing neurons on ventrolateral periaqueductal gray improves behavioral hypersensitivity and thalamic discharge in a trigeminal neuralgia rat model

Inflammatory complications of CGRP monoclonal antibodies: a case series

HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism

Medication overuse and drug addiction: a narrative review from addiction perspective

Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice